Author: Dan

In the September 14 issue of the journal Neurology, Alzheimer’s experts have offered their opinions in one editorial and two viewpoint papers, one pro and one against, concerning the FDA approval of aducanumab, now known...

Ever since Dr. Allen Roses and his group at Duke reported in the 1990s that people carrying the APOE-4 gene are at greater risk for getting Alzheimer’s, there has been uncertainty about how a gene that...

Abnormal tau protein is found in the neurofibrillary tangles found in nerve cells in the brain starting a few years before the onset of cognitive impairment in Alzheimer’s disease. Most drug trials attempting to...

Increasing evidence has shown that getting too little sleep increases the risk of developing dementia.  In one recent study those routinely getting 6 or less hours of sleep had a significantly greater chance of developing...

Now that Aduhelm (aducanumab) has been approved by the FDA for people with early-stage Alzheimer’s, those with mild cognitive impairment or mild dementia, who will be responsible for the $56,000 annual price tag? A...

A recurring theme of my blog has been that our best shot at attacking Alzheimer’s disease is in the earliest stage, before cognitive impairment has started. We now know that the first pathological signs...

Yesterday I came across an interesting paper from 2013 in Lancet Neurology that adds important information about the case of Auguste D, the first patient diagnosed with what was later called Alzheimer’s disease. I mentioned this...